VIRACEPT
LOE Approachingnelfinavir mesylate
NDAORALPOWDERPriority Review
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIRACEPT (nelfinavir mesylate) is an oral protease inhibitor approved in 1997 for the treatment of HIV infection. It works by inhibiting HIV protease, an enzyme essential for viral replication, thereby reducing viral load in infected patients. This small-molecule antiviral represents a foundational class in modern HIV combination antiretroviral therapy.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), commercial teams are likely consolidating and transitioning to post-LOE maintenance mode rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Started Mar 2017
36 enrolled
Recurrent Kaposi SarcomaSkin Kaposi Sarcoma
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
Started Mar 2006
16 enrolled
HIV Infection
Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen
Started Aug 2002
179 enrolled
Human Immunodeficiency Virus
Career Relevance
Career opportunities on VIRACEPT are limited and primarily defensive in nature, focused on market maintenance and regulatory compliance rather than growth initiatives. Professionals taking roles on this product should expect stability in established markets but limited advancement or exposure to expanding therapeutic programs.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.